Sangamo Licenses Zinc Finger Nuclease Reagents to Pfizer | GenomeWeb
NEW YORK (GenomeWeb News) – Sangamo BioSciences today said that it has licensed to Pfizer the use of certain zinc finger protein nuclease reagents for use in clinical and commercial production of therapeutic proteins.
 
The Richmond, Calif.-based firm said that it had licensed to Pfizer non-exclusive, worldwide rights to use the reagents to permanently eliminate the glutamine synthetase gene in Chinese Hamster Ovary cell lines. The cells will be used for producing the therapeutic proteins.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.